Bortezomib

Name: Bortezomib

Why is this medication prescribed?

Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with at least one other medication. Bortezomib is also used to treat people with mantle cell lymphoma (a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other medication. Bortezomib is in a class of medications called antineoplastic agents. It works by killing cancer cells.

Adverse Effects

>10%

Asthenia (61-65%)

Nausea (61-65%)

Diarrhea (51-55%)

Anorexia (41-45%)

Constipation (41-45%)

Thrombocytopenia (41-45%)

Peripheral neuropathy (IV: 16-41%; SC: 6-24%)

Pyrexia (36-40%)

Vomiting (36-40%)

Anemia (31-35%)

Arthralgia (26-30%)

Headache (26-30%)

Insomnia (26-30%)

Limb pain (26-30%)

Dizziness (21-25%)

Dyspnea (21-25%)

Edema (21-25%)

Neutropenia (21-25%)

Paresthesia (21-25%)

Rash (21-25%)

Cough (15-20%)

Dehydration (15-20%)

URI (15-20%)

Rigors, grade 4 toxicity (10-15%)

Frequency Not Defined

Hypotension

Anxiety

Pain

Pruritis

Abdominal pain

Dyspepsia

Back pain

Bone pain

Myalgia

Muscle spasms

Herpes zoster

Pneumonia

Blurred vision

Postmarketing Reports

Cardiovascular: Atrioventricular block complete, cardiac tamponade

GI: Ischemic colitis, hepatitis, acute pancreatitis

CNS: Encephalopathy, dysautonomia, progressive multifocal leukoencephalopathy (PML), acute diffuse infiltrative pulmonary disease, PRES (formerly RPLS), herpes meningoencephalitis

Hematologic: Disseminated intravascular coagulation

Pulmonary: Acute diffuse infiltrative pulmonary disease

Skin: Toxic epidermal necrolysis, acute febrile neutrophilic dermatosis (Sweet’s syndrome)

Sensory: Optic neuropathy, deafness bilateral, blindness, and ophthalmic herpes

Pregnancy & Lactation

Pregnancy

Based on mechanism of action and findings in animals, therapy can cause fetal harm when administered to a pregnant woman; there are no studies in pregnant women to inform drug-associated risks; therapy caused embryo-fetal lethality in rabbits at doses lower than the clinical dose; advise pregnant women of potential risk to fetus

Verify pregnancy status of females of reproductive potential prior to initiating treatment

Advise patients of reproductive potential to use effective contraception during treatment with therapy and for at least 2 months after treatment

Lactation

There are no data on presence of bortezomib or metabolites in human milk, the effects of the drug on the breast fed infant or on milk production; because many drugs are excreted in human milk and because potential for serious adverse reactions in breastfed infants from therapy is unknown, advise nursing women not to breastfeed during treatment and for 2 months after treatment

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

Bortezomib Usage

Bortezomib is an injectable medication that is administered by healthcare provider in a medical setting. It may be given intravenously (into a vein) or subcutaneously (just under the skin), usually in the thigh or stomach.

Bortezomib is usually given once or twice a week. Doses are always at least 72 hours (three days) apart.

Your doctor may tell you to take other medicines while receiving bortezomib. Follow these instructions carefully.

Bortezomib Dosage

The bortezomib dose you receive is based on your height and weight which is used to calculate your body surface area. It is usually injected 2 times a week for 2 weeks, followed by 10 days without an injection. Bortezomib may also be given once a week for 4 weeks followed by 13 days without an injection. Follow your doctor's instructions about your individual dosing schedule. It is important to keep all of your appointments to receive your bortezomib dose.

If side effects become intolerable, you may need to wait longer between doses, receive a lower dose, or permanently stop the medicine if potentially serious side effects occur.

How is bortezomib given?

Bortezomib is injected into a vein through an IV.

You will receive this injection in a clinic or hospital setting. A doctor, nurse, or other healthcare provider will give you this injection.

You may be given medication to prevent nausea or vomiting while you are receiving bortezomib.

Bortezomib can lower blood cells that help your body fight infections and help your blood to clot. Your blood will need to be tested often. Your cancer treatments may be delayed based on the results of these tests.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What other drugs will affect bortezomib?

Many drugs can interact with bortezomib. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Tell your doctor about all medicines you use, and those you start or stop using during your treatment with bortezomib. Give a list of all your medicines to any healthcare provider who treats you.

Introduction

Antineoplastic agent; inhibitor of 26S proteasome.1 5

What are some things I need to know or do while I take Bortezomib?

  • Tell all of your health care providers that you take bortezomib. This includes your doctors, nurses, pharmacists, and dentists.
  • Avoid driving and doing other tasks or actions that call for you to be alert until you see how this medicine affects you.
  • To lower the chance of feeling dizzy or passing out, rise slowly if you have been sitting or lying down. Be careful going up and down stairs.
  • You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.
  • Call your doctor right away if you have any signs of infection like fever, chills, flu-like signs, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, or a wound that will not heal.
  • You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.
  • Heart failure has happened with bortezomib, as well as heart failure that has gotten worse in people who already have it. Tell your doctor if you have heart disease. Call your doctor right away if you have shortness of breath, a big weight gain, a heartbeat that is not normal, or swelling in the arms or legs that is new or worse.
  • Nerve problems like numbness, pain, or a burning feeling in the feet or hands can happen in people taking this medicine and may get worse in people who already have them. Call your doctor right away if you have signs of nerve problems like not able to handle heat or cold, a lower sense of touch, or burning, numbness, tingling, pain, or weakness in the arms, hands, legs, or feet.
  • A very bad brain problem called progressive multifocal leukoencephalopathy (PML) has happened with bortezomib. It may cause disability or can be deadly. Tell your doctor right away if you have signs like confusion, memory problems, low mood (depression), change in the way you act, change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or change in eyesight.
  • This medicine may affect fertility. Fertility problems may lead to not being able to get pregnant or father a child. Talk with the doctor.
  • If you are a man and have sex with a female who could get pregnant, protect her from pregnancy during care and for 2 months after stopping this medicine. Use birth control that you can trust.
  • If you are a man and your sex partner gets pregnant while you take bortezomib or within 2 months after your last dose, call your doctor right away.
  • This medicine may cause harm to the unborn baby if you take it while you are pregnant.
  • If you are able to get pregnant, a pregnancy test will be done to show that you are NOT pregnant before starting this medicine. Talk with your doctor.
  • Use birth control that you can trust during care and for 2 months after care ends.
  • If you get pregnant while taking bortezomib or within 2 months after your last dose, call your doctor right away.

What are some side effects that I need to call my doctor about right away?

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

  • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
  • Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes.
  • Signs of high or low blood pressure like very bad headache or dizziness, passing out, change in eyesight.
  • Weakness on 1 side of the body, trouble speaking or thinking, change in balance, drooping on one side of the face, or blurred eyesight.
  • Very bad belly pain.
  • Very hard stools (constipation).
  • Any unexplained bruising or bleeding.
  • Throwing up blood or throw up that looks like coffee grounds.
  • Black, tarry, or bloody stools.
  • Feeling very tired or weak.
  • Irritation where the shot is given.
  • Very bad and sometimes deadly lung problems have happened with bortezomib. Call your doctor right away if you have lung or breathing problems like trouble breathing, shortness of breath, or a cough that is new or worse.
  • Patients with cancer who take this medicine may be at a greater risk of getting a bad health problem called tumor lysis syndrome (TLS). Sometimes, this has been deadly. Call your doctor right away if you have a fast heartbeat or a heartbeat that does not feel normal; any passing out; trouble passing urine; muscle weakness or cramps; upset stomach, throwing up, loose stools, or not able to eat; or feel sluggish.
  • A very bad and sometimes deadly brain problem called posterior reversible encephalopathy syndrome (PRES) has happened with bortezomib. Call your doctor right away if you have signs like feeling confused, lowered alertness, change in eyesight, loss of eyesight, seizures, or very bad headache.

Consumer Information Use and Disclaimer

  • If your symptoms or health problems do not get better or if they become worse, call your doctor.
  • Do not share your drugs with others and do not take anyone else's drugs.
  • Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
  • Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Check with your pharmacist about how to throw out unused drugs.
  • Some drugs may have another patient information leaflet. Check with your pharmacist. If you have any questions about bortezomib, please talk with your doctor, nurse, pharmacist, or other health care provider.
  • If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about bortezomib. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using bortezomib.

Review Date: October 4, 2017

Brand Names U.S.

  • Velcade

Dietary Considerations

Green tea and green tea extracts may diminish the therapeutic effect of bortezomib and should be avoided (Golden 2009). Avoid grapefruit juice. Avoid additional, nondietary sources of ascorbic acid supplements, including multivitamins containing ascorbic acid (may diminish bortezomib activity) during treatment, especially 12 hours before and after bortezomib treatment (Perrone 2009).

Side effects

The following adverse reactions are also discussed in other sections of the labeling:

  • Peripheral Neuropathy [see WARNINGS AND PRECAUTIONS]
  • Hypotension [see WARNINGS AND PRECAUTIONS]
  • Cardiac Toxicity[see WARNINGS AND PRECAUTIONS]
  • Pulmonary Toxicity [see WARNINGS AND PRECAUTIONS]
  • Posterior Reversible Encephalopathy Syndrome (PRES) [see WARNINGS AND PRECAUTIONS]
  • Gastrointestinal Toxicity [see WARNINGS AND PRECAUTIONS]
  • Thrombocytopenia/Neutropenia [see WARNINGS AND PRECAUTIONS]
  • Tumor Lysis Syndrome [see WARNINGS AND PRECAUTIONS]
  • Hepatic Toxicity [see WARNINGS AND PRECAUTIONS]

Clinical Trials Safety Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Summary Of Clinical Trial In Patients With Previously Untreated Multiple Myeloma

Table 9 describes safety data from 340 patients with previously untreated multiple myeloma who received VELCADE (1.3 mg/m2) administered intravenously in combination with melphalan (9 mg/m2) and prednisone (60 mg/m2) in a prospective randomized study.

The safety profile of VELCADE in combination with melphalan/prednisone is consistent with the known safety profiles of both VELCADE and melphalan/prednisone.

Table 9: Most Commonly Reported Adverse Reactions (≥ 10% in the VELCADE, Melphalan and Prednisone arm) with Grades 3 and ≥ 4 Intensity in the Previously Untreated Multiple Myeloma Study

  VELCADE, Melphalan and Prednisone
(n=340)
Melphalan and Prednisone
(n=337)
System Organ Class Total Toxicity Grade, n (%) Total Toxicity Grade, n (%)
Preferred Term n (%) 3 ≥ 4 n (%) 3 ≥ 4
Blood and lymphatic system disorders
  Thrombocytopenia 164 (48) 60 (18) 57 (17) 140 (42) 48 (14) 39 (12)
  Neutropenia 160 (47) 101 (30) 33 (10) 143 (42) 77 (23) 42 (12)
  Anemia 108 (32) 64 (19) 8 (2) 93 (28) 53 (16) 11 (3)
  Lymphopenia 78 (23) 46 (14) 17 (5) 51 (15) 26 (8) 7 (2)
Gastrointestinal disorders
  Nausea 134 (39) 10 (3) 0 70 (21) 1 (< 1) 0
  Diarrhea 119 (35) 19 (6) 2 (1) 20 (6) 1 (< 1) 0
  Vomiting 87 (26) 13 (4) 0 41 (12) 2 (1) 0
  Constipation 77 (23) 2 (1) 0 14 (4) 0 0
  Abdominal Pain Upper 34 (10) 1 (< 1) 0 20 (6) 0 0
Nervous system disorders
  Peripheral Neuropathya 156 (46) 42 (12) 2 (1) 4 (1) 0 0
  Neuralgia 117 (34) 27 (8) 2 (1) 1 (< 1) 0 0
  Paresthesia 42 (12) 6 (2) 0 4 (1) 0 0
General disorders and administration site
conditions
  Fatigue 85 (25) 19 (6) 2 (1) 48 (14) 4 (1) 0
  Asthenia 54 (16) 18 (5) 0 23 (7) 3 (1) 0
  Pyrexia 53 (16) 4 (1) 0 19 (6) 1 (< 1) 1 (< 1)
Infections and infestations
  Herpes Zoster 39 (11) 11 (3) 0 9 (3) 4 (1) 0
Metabolism and nutrition disorders
  Anorexia 64 (19) 6 (2) 0 19 (6) 0 0
Skin and subcutaneous tissue disorders
  Rash 38 (11) 2 (1) 0 7 (2) 0 0
Psychiatric disorders
  Insomnia 35 (10) 1 (< 1) 0 21 (6) 0 0
a Represents High Level Term Peripheral Neuropathies NEC

Relapsed Multiple Myeloma Randomized Study Of VELCADE Versus Dexamethasone

The safety data described below and in Table 10 reflect exposure to either VELCADE (n=331) or dexamethasone (n=332) in a study of patients with relapsed multiple myeloma. VELCADE was administered intravenously at doses of 1.3 mg/m2 twice weekly for 2 out of 3 weeks (21-day cycle). After eight 21-day cycles patients continued therapy for three 35-day cycles on a weekly schedule. Duration of treatment was up to 11 cycles (9 months) with a median duration of 6 cycles (4.1 months). For inclusion in the trial, patients must have had measurable disease and 1 to 3 prior therapies. There was no upper age limit for entry. Creatinine clearance could be as low as 20 mL/min and bilirubin levels as high as 1.5 times the upper limit of normal. The overall frequency of adverse reactions was similar in men and women, and in patients < 65 and ≥ 65 years of age. Most patients were Caucasian [see Clinical Studies].

Among the 331 VELCADE-treated patients, the most commonly reported (> 20%) adverse reactions overall were nausea (52%), diarrhea (52%), fatigue (39%), peripheral neuropathies (35%), thrombocytopenia (33%), constipation (30%), vomiting (29%), and anorexia (21%). The most commonly reported (> 20%) adverse reaction reported among the 332 patients in the dexamethasone group was fatigue (25%). Eight percent (8%) of patients in the VELCADE-treated arm experienced a Grade 4 adverse reaction; the most common reactions were thrombocytopenia (4%) and neutropenia (2%). Nine percent (9%) of dexamethasone-treated patients experienced a Grade 4 adverse reaction. All individual dexamethasone-related Grade 4 adverse reactions were less than 1%.

Serious Adverse Reactions And Adverse Reactions Leading To Treatment Discontinuation In The Relapsed Multiple Myeloma Study Of VELCADE Versus Dexamethasone

Serious adverse reactions are defined as any reaction that results in death, is life-threatening, requires hospitalization or prolongs a current hospitalization, results in a significant disability, or is deemed to be an important medical event. A total of 80 (24%) patients from the VELCADE treatment arm experienced a serious adverse reaction during the study, as did 83 (25%) dexamethasone-treated patients. The most commonly reported serious adverse reactions in the VELCADE treatment arm were diarrhea (3%), dehydration, herpes zoster, pyrexia, nausea, vomiting, dyspnea, and thrombocytopenia (2% each). In the dexamethasone treatment group, the most commonly reported serious adverse reactions were pneumonia (4%), hyperglycemia (3%), pyrexia, and psychotic disorder (2% each).

A total of 145 patients, including 84 (25%) of 331 patients in the VELCADE treatment group and 61 (18%) of 332 patients in the dexamethasone treatment group were discontinued from treatment due to adverse reactions. Among the 331 VELCADE treated patients, the most commonly reported adverse reaction leading to discontinuation was peripheral neuropathy (8%). Among the 332 patients in the dexamethasone group, the most commonly reported adverse reactions leading to treatment discontinuation were psychotic disorder and hyperglycemia (2% each).

Four deaths were considered to be VELCADE-related in this relapsed multiple myeloma study: 1 case each of cardiogenic shock, respiratory insufficiency, congestive heart failure and cardiac arrest. Four deaths were considered dexamethasone-related: 2 cases of sepsis, 1 case of bacterial meningitis, and 1 case of sudden death at home.

Most Commonly Reported Adverse Reactions In The Relapsed Multiple Myeloma Study Of VELCADE Versus Dexamethasone

The most common adverse reactions from the relapsed multiple myeloma study are shown in Table 10. All adverse reactions with incidence ≥ 10% in the VELCADE arm are included.

Table 10: Most Commonly Reported Adverse Reactions (≥ 10% in VELCADE arm), with Grades 3 and 4 Intensity in the Relapsed Multiple Myeloma Study of VELCADE versus Dexamethasone (N=663)

  VELCADE
N=331
Dexamethasone
N=332
Preferred Term All Grade 3 Grade 4 All Grade 3 Grade 4
Adverse Reactions 324 (98) 193 (58) 28 (8) 297 (89) 110 (33) 29 (9)
Nausea 172 (52) 8 (2) 0 31 (9) 0 0
Diarrhea NOS 171 (52) 22 (7) 0 36 (11) 2 (< 1) 0
Fatigue 130 (39) 15 (5) 0 82 (25) 8 (2) 0
Peripheral neuropathiesa 115 (35) 23 (7) 2 (< 1) 14 (4) 0 1 (< 1)
Thrombocytopenia 109 (33) 80 (24) 12 (4) 11 (3) 5 (2) 1 (< 1)
Constipation 99 (30) 6 (2) 0 27 (8) 1 (< 1) 0
Vomiting NOS 96 (29) 8 (2) 0 10 (3) 1 (< 1) 0
Anorexia 68 (21) 8 (2) 0 8 (2) 1 (< 1) 0
Pyrexia 66 (20) 2 (< 1) 0 21 (6) 3 (< 1) 1 (< 1)
Paresthesia 64 (19) 5 (2) 0 24 (7) 0 0
Anemia NOS 63 (19) 20 (6) 1 (< 1) 21 (6) 8 (2) 0
Headache NOS 62 (19) 3 (< 1) 0 23 (7) 1 (< 1) 0
Neutropenia 58 (18) 37 (11) 8 (2) 1 (< 1) 1 (< 1) 0
Rash NOS 43 (13) 3 (< 1) 0 7 (2) 0 0
Appetite decreased NOS 36 (11) 0 0 12 (4) 0 0
Dyspnea NOS 35 (11) 11 (3) 1 (< 1) 37 (11) 7 (2) 1 (< 1)
Abdominal pain NOS 35 (11) 5 (2) 0 7 (2) 0 0
Weakness 34 (10) 10 (3) 0 28 (8) 8 (2) 0
a Represents High Level Term Peripheral Neuropathies NEC

Safety Experience From The Phase 2 Open-Label Extension Study In Relapsed Multiple Myeloma

In the phase 2 extension study of 63 patients, no new cumulative or new long-term toxicities were observed with prolonged VELCADE treatment. These patients were treated for a total of 5.3 to 23 months, including time on VELCADE in the prior VELCADE study [see Clinical Studies].

Safety Experience From The Phase 3 Open-Label Study Of VELCADE Subcutaneous Versus Intravenous In Relapsed Multiple Myeloma

The safety and efficacy of VELCADE administered subcutaneously were evaluated in one Phase 3 study at the recommended dose of 1.3 mg/m2. This was a randomized, comparative study of VELCADE subcutaneous versus intravenous in 222 patients with relapsed multiple myeloma. The safety data described below and in Table 11 reflect exposure to either VELCADE subcutaneous (n=147) or VELCADE intravenous (n=74) [see Clinical Studies].

Table 11: Most Commonly Reported Adverse Reactions (≥ 10%), with Grade 3 and ≥ 4 Intensity in theRelapsed Multiple Myeloma Study (N=221) of VELCADE Subcutaneous versus Intravenous

  Subcutaneous
(N=147)
Intravenous
(N=74)
System Organ Class Total Toxicity Grade, n (%) Total Toxicity Grade, n (%)
Preferred Term n (%) 3 ≥ 4 n (%) 3 ≥ 4
Blood and lymphatic system disorders
  Anemia 28 (19) 8 (5) 0 17 (23) 3 (4) 0
  Leukopenia 26 (18) 8 (5) 0 15 (20) 4 (5) 1 (1)
  Neutropenia 34 (23) 15 (10) 4 (3) 20 (27) 10 (14) 3 (4)
  Thrombocytopenia 44 (30) 7 (5) 5 (3) 25 (34) 7 (9) 5 (7)
Gastrointestinal disorders
  Diarrhea 28 (19) 1 (1) 0 21 (28) 3 (4) 0
  Nausea 24 (16) 0 0 10 (14) 0 0
  Vomiting 13 (9) 3 (2) 0 8 (11) 0 0
General disorders and administration site
conditions
  Asthenia 10 (7) 1 (1) 0 12 (16) 4 (5) 0
  Fatigue 11 (7) 3 (2) 0 11 (15) 3 (4) 0
  Pyrexia 18 (12) 0 0 6 (8) 0 0
Nervous system disorders
  Neuralgia 34 (23) 5 (3) 0 17 (23) 7 (9) 0
  Peripheral neuropathiesa 55 (37) 8 (5) 1 (1) 37 (50) 10 (14) 1 (1)
Note: Safety population: 147 patients in the subcutaneous treatment group and 74 patients in the intravenous treatment group who received at least 1 dose of study medication
a Represents High Level Term Peripheral Neuropathies NEC

In general, safety data were similar for the subcutaneous and intravenous treatment groups. Differences were observed in the rates of some Grade ≥ 3 adverse reactions. Differences of ≥ 5% were reported in neuralgia (3% subcutaneous versus 9% intravenous), peripheral neuropathies (6% subcutaneous versus 15% intravenous), neutropenia (13% subcutaneous versus 18% intravenous), and thrombocytopenia (8% subcutaneous versus 16% intravenous).

A local reaction was reported in 6% of patients in the subcutaneous group, mostly redness. Only 2 (1%) patients were reported as having severe reactions, 1 case of pruritus and 1 case of redness. Local reactions led to reduction in injection concentration in one patient and drug discontinuation in one patient. Local reactions resolved in a median of 6 days.

Dose reductions occurred due to adverse reactions in 31% of patients in the subcutaneous treatment group compared with 43% of the intravenously-treated patients. The most common adverse reactions leading to a dose reduction included peripheral sensory neuropathy (17% in the subcutaneous treatment group compared with 31% in the intravenous treatment group); and neuralgia (11% in the subcutaneous treatment group compared with 19% in the intravenous treatment group).

Serious Adverse Reactions And Adverse Reactions Leading To Treatment Discontinuation In The Relapsed Multiple Myeloma Study Of VELCADE Subcutaneous Versus Intravenous

The incidence of serious adverse reactions was similar for the subcutaneous treatment group (20%) and the intravenous treatment group (19%). The most commonly reported serious adverse reactions in the subcutaneous treatment arm were pneumonia and pyrexia (2% each). In the intravenous treatment group, the most commonly reported serious adverse reactions were pneumonia, diarrhea, and peripheral sensory neuropathy (3% each).

In the subcutaneous treatment group, 27 patients (18%) discontinued study treatment due to an adverse reaction compared with 17 patients (23%) in the intravenous treatment group. Among the 147 subcutaneously-treated patients, the most commonly reported adverse reactions leading to discontinuation were peripheral sensory neuropathy (5%) and neuralgia (5%). Among the 74 patients in the intravenous treatment group, the most commonly reported adverse reactions leading to treatment discontinuation were peripheral sensory neuropathy (9%) and neuralgia (9%).

Two patients (1%) in the subcutaneous treatment group and 1 (1%) patient in the intravenous treatment group died due to an adverse reaction during treatment. In the subcutaneous group the causes of death were one case of pneumonia and one case of sudden death. In the intravenous group the cause of death was coronary artery insufficiency.

Safety Experience From The Clinical Trial In Patients With Previously Untreated Mantle Cell Lymphoma

Table 12 describes safety data from 240 patients with previously untreated mantle cell lymphoma who received VELCADE (1.3 mg/m2) administered intravenously in combination with rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and prednisone (100 mg/m2) (VcR-CAP) in a prospective randomized study.

Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the comparator (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) arm, including the predominant preferred term of pneumonia (VcR-CAP 8% versus R-CHOP 5%).

Table 12: Most Commonly Reported Adverse Reactions (≥ 5%) with Grades 3 and ≥ 4 Intensity in the Previously Untreated Mantle Cell Lymphoma Study

n (%) n (%)
  VcR-CAP
n=240
R-CHOP
n=242
System Organ Class All Toxicity
Grade 3
Toxicity
Grade ≥4
All Toxicity
Grade 3
Toxicity
Grade ≥4
Preferred Term n (%) n (%)n (%) n (%) n (%)n (%)
Blood and lymphatic system disorders
  Neutropenia 209 (87) 32 (13) 168 (70) 172 (71) 31 (13) 125 (52)
  Leukopenia 116 (48) 34 (14) 69 (29) 87 (36) 39 (16) 27 (11)
  Anemia 106 (44) 27 (11) 4 (2) 71 (29) 23 (10) 4 (2)
  Thrombocytopenia 172 (72) 59 (25) 76 (32) 42 (17) 9 (4) 3 (1)
  Febrile neutropenia 41 (17) 24 (10) 12 (5) 33 (14) 17 (7) 15 (6)
  Lymphopenia 68 (28) 25 (10) 36 (15) 28 (12) 15 (6) 2 (1)
Nervous system disorders
  Peripheral neuropathya 71 (30) 17 (7) 1 (< 1) 65 (27) 10 (4) 0
  Hypoesthesia 14 (6) 3 (1) 0 13 (5) 0 0
  Paresthesia 14 (6) 2 (1) 0 11 (5) 0 0
  Neuralgia 25 (10) 9 (4) 0 1 (< 1) 0 0
General disorders and administration site
conditions
  Fatigue 43 (18) 11 (5) 1 (< 1) 38 (16) 5 (2) 0
  Pyrexia 48 (20) 7 (3) 0 23 (10) 5 (2) 0
  Asthenia 29 (12) 4 (2) 1 (< 1) 18 (7) 1 (< 1) 0
  Edema peripheral 16 (7) 1 (< 1) 0 13 (5) 0 0
Gastrointestinal disorders
  Nausea 54 (23) 1 (< 1) 0 28 (12) 0 0
  Constipation 42 (18) 1 (< 1) 0 22 (9) 2 (1) 0
  Stomatitis 20 (8) 2 (1) 0 19 (8) 0 1 (< 1)
  Diarrhea 59 (25) 11 (5) 0 11 (5) 3 (1) 1 (< 1)
  Vomiting 24 (10) 1 (< 1) 0 8 (3) 0 0
  Abdominal distension 13 (5) 0 0 4 (2) 0 0
Infections and infestations
  Pneumonia 20 (8) 8 (3) 5 (2) 11 (5) 5 (2) 3 (1)
Skin and subcutaneous tissue
disorders
  Alopecia 31 (13) 1 (< 1) 1 (< 1) 33 (14) 4 (2) 0
Metabolism and nutrition
disorders
  Hyperglycemia 10 (4) 1 (< 1) 0 17 (7) 10 (4) 0
  Decreased appetite 36 (15) 2 (1) 0 15 (6) 1 (< 1) 0
Vascular disorders
  Hypertension 15 (6) 1 (< 1) 0 3 (1) 0 0
Psychiatric disorders
  Insomnia 16 (7) 1 (< 1) 0 8 (3) 0 0
Key: R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone;
VcR-CAP=VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone.
a Represents High Level Term Peripheral Neuropathies NEC

The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm. Antiviral prophylaxis was mandated by protocol amendment.

The incidences of Grade ≥ 3 bleeding events were similar between the 2 arms (3 patients in the VcR-CAP arm and 1 patient in the R-CHOP arm). All of the Grade ≥ 3 bleeding events resolved without sequelae in the VcR-CAP arm.

Adverse reactions leading to discontinuation occurred in 8% of patients in VcR-CAP group and 6% of patients in R-CHOP group. In the VcR-CAP group, the most commonly reported adverse reaction leading to discontinuation was peripheral sensory neuropathy (1%; 3 patients). The most commonly reported adverse reaction leading to discontinuation in the R-CHOP group was febrile neutropenia (< 1%; 2 patients).

Integrated Summary Of Safety (Relapsed Multiple Myeloma And Relapsed Mantle Cell Lymphoma)

Safety data from phase 2 and 3 studies of single agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with previously-treated multiple myeloma (N=1008) and previously-treated mantle cell lymphoma (N=155) were integrated and tabulated. This analysis does not include data from the Phase 3 Open-Label Study of VELCADE subcutaneous versus intravenous in relapsed multiple myeloma. In the integrated studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported (> 20%) adverse reactions were nausea (49%), diarrhea (46%), asthenic conditions including fatigue (41%) and weakness (11%), peripheral neuropathies (38%), thrombocytopenia (32%), vomiting (28%), constipation (25%), and pyrexia (21%). Eleven percent (11%) of patients experienced at least 1 episode of ≥ Grade 4 toxicity, most commonly thrombocytopenia (4%) and neutropenia (2%).

In the Phase 2 relapsed multiple myeloma clinical trials of VELCADE administered intravenously, local skin irritation was reported in 5% of patients, but extravasation of VELCADE was not associated with tissue damage.

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Integrated Summary of Safety

A total of 26% of patients experienced a serious adverse reaction during the studies. The most commonly reported serious adverse reactions included diarrhea, vomiting and pyrexia (3% each), nausea, dehydration, and thrombocytopenia (2% each) and pneumonia, dyspnea, peripheral neuropathies, and herpes zoster (1% each).

Adverse reactions leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), and fatigue, thrombocytopenia, and diarrhea (2% each).

In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

Most Commonly Reported Adverse Reactions In The Integrated Summary Of Safety

The most common adverse reactions are shown in Table 13. All adverse reactions occurring at ≥ 10% are included. In the absence of a randomized comparator arm, it is often not possible to distinguish between adverse events that are drug-caused and those that reflect the patient’s underlying disease. Please see the discussion of specific adverse reactions that follows.

Table 13: Most Commonly Reported (≥ 10% Overall) Adverse Reactions in Integrated Analyses of Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma Studiesusing the 1.3 mg/m2 Dose (N=1163)

  All Patients
N=1163
Multiple Myeloma
N=1008
Mantle Cell Lymphoma
N=155
Preferred Term All ≥ Grade 3 All ≥ Grade 3 All ≥ Grade 3
Nausea 567 (49) 36 (3) 511 (51) 32 (3) 56 (36) 4 (3)
Diarrhea NOS 530 (46) 83 (7) 470 (47) 72 (7) 60 (39) 11 (7)
Fatigue 477 (41) 86 (7) 396 (39) 71 (7) 81 (52) 15 (10)
Peripheral neuropathiesa 443 (38) 129 (11) 359 (36) 110 (11) 84 (54) 19 (12)
Thrombocytopenia 369 (32) 295 (25) 344 (34) 283 (28) 25 (16) 12 (8)
Vomiting NOS 321 (28) 44 (4) 286 (28) 40 (4) 35 (23) 4 (3)
Constipation 296 (25) 17 (1) 244 (24) 14 (1) 52 (34) 3 (2)
Pyrexia 249 (21) 16 (1) 233 (23) 15 (1) 16 (10) 1 (< 1)
Anorexia 227 (20) 19 (2) 205 (20) 16 (2) 22 (14) 3 (2)
Anemia NOS 209 (18) 65 (6) 190 (19) 63 (6) 19 (12) 2 (1)
Headache NOS 175 (15) 8 (< 1) 160 (16) 8 (< 1) 15 (10) 0
Neutropenia 172 (15) 121 (10) 164 (16) 117 (12) 8 (5) 4 (3)
Rash NOS 156 (13) 8 (< 1) 120 (12) 4 (< 1) 36 (23) 4 (3)
Paresthesia 147 (13) 9 (< 1) 136 (13) 8 (< 1) 11 (7) 1 (< 1)
Dizziness (excl vertigo) 129 (11) 13 (1) 101 (10) 9 (< 1) 28 (18) 4 (3)
Weakness 124 (11) 31 (3) 106 (11) 28 (3) 18 (12) 3 (2)
a Represents High Level Term Peripheral Neuropathies NEC

Description Of Selected Adverse Reactions From The Integrated Phase 2 And 3 Relapsed Multiple Myeloma And Phase 2 Relapsed Mantle Cell Lymphoma Studies

Gastrointestinal Toxicity

A total of 75% of patients experienced at least one gastrointestinal disorder. The most common gastrointestinal disorders included nausea, diarrhea, constipation, vomiting, and appetite decreased. Other gastrointestinal disorders included dyspepsia and dysgeusia. Grade 3 adverse reactions occurred in 14% of patients; ≥ Grade 4 adverse reactions were ≤ 1%. Gastrointestinal adverse reactions were considered serious in 7% of patients.Four percent (4%) of patients discontinued due to a gastrointestinal adverse reaction. Nausea was reported more often in patients with multiple myeloma (51%) compared to patients with mantle cell lymphoma (36%).

Thrombocytopenia

Across the studies, VELCADE-associated thrombocytopenia was characterized by a decrease in platelet count during the dosing period (days 1 to 11) and a return toward baseline during the 10-day rest period during each treatment cycle. Overall, thrombocytopenia was reported in 32% of patients. Thrombocytopenia was Grade 3 in 22%, ≥ Grade 4 in 4%, and serious in 2% of patients, and the reaction resulted in VELCADE discontinuation in 2% of patients [see WARNINGS AND PRECAUTIONS]. Thrombocytopenia was reported more often in patients with multiple myeloma (34%) compared to patients with mantle cell lymphoma (16%). The incidence of ≥ Grade 3 thrombocytopenia also was higher in patients with multiple myeloma (28%) compared to patients with mantle cell lymphoma (8%).

Peripheral Neuropathy

Overall, peripheral neuropathies occurred in 38% of patients. Peripheral neuropathy was Grade 3 for 11% of patients and ≥ Grade 4 for < 1% of patients. Eight percent (8%) of patients discontinued VELCADE due to peripheral neuropathy. The incidence of peripheral neuropathy was higher among patients with mantle cell lymphoma (54%) compared to patients with multiple myeloma (36%).

In the VELCADE versus dexamethasone phase 3 relapsed multiple myeloma study, among the 62 VELCADE-treated patients who experienced ≥ Grade 2 peripheral neuropathy and had dose adjustments, 48% had improved or resolved with a median of 3.8 months from first onset.

In the phase 2 relapsed multiple myeloma studies, among the 30 patients who experienced Grade 2 peripheral neuropathy resulting in discontinuation or who experienced ≥ Grade 3 peripheral neuropathy, 73% reported improvement or resolution with a median time of 47 days to improvement of one Grade or more from the last dose of VELCADE.

Hypotension

The incidence of hypotension (postural, orthostatic and hypotension NOS) was 8% in patients treated with VELCADE. Hypotension was Grade 1 or 2 in the majority of patients and Grade 3 in 2% and ≥ Grade 4 in < 1%. Two percent (2%) of patients had hypotension reported as a serious adverse reaction, and 1% discontinued due to hypotension. The incidence of hypotension was similar in patients with multiple myeloma (8%) and those with mantle cell lymphoma (9%). In addition, < 1% of patients experienced hypotension associated with a syncopal reaction.

Neutropenia

Neutrophil counts decreased during the VELCADE dosing period (days 1 to 11) and returned toward baseline during the 10-day rest period during each treatment cycle. Overall, neutropenia occurred in 15% of patients and was Grade 3 in 8% of patients and ≥ Grade 4 in 2%. Neutropenia was reported as a serious adverse reaction in < 1% of patients and < 1% of patients discontinued due to neutropenia. The incidence of neutropenia was higher in patients with multiple myeloma (16%) compared to patients with mantle cell lymphoma (5%). The incidence of ≥ Grade 3 neutropenia also was higher in patients with multiple myeloma (12%) compared to patients with mantle cell lymphoma (3%).

Asthenic conditions (Fatigue, Malaise, Weakness, Asthenia)

Asthenic conditions were reported in 54% of patients. Fatigue was reported as Grade 3 in 7% and ≥ Grade 4 in < 1% of patients. Asthenia was reported as Grade 3 in 2% and ≥ Grade 4 in < 1% of patients. Two percent (2%) of patients discontinued treatment due to fatigue and < 1% due to weakness and asthenia. Asthenic conditions were reported in 53% of patients with multiple myeloma and 59% of patients with mantle cell lymphoma.

Pyrexia

Pyrexia (> 38°C) was reported as an adverse reaction for 21% of patients. The reaction was Grade 3 in 1% and ≥ Grade 4 in < 1%. Pyrexia was reported as a serious adverse reaction in 3% of patients and led to VELCADE discontinuation in < 1% of patients. The incidence of pyrexia was higher among patients with multiple myeloma (23%) compared to patients with mantle cell lymphoma (10%). The incidence of ≥ Grade 3 pyrexia was 1% in patients with multiple myeloma and < 1% in patients with mantle cell lymphoma.

Herpes Virus Infection

Consider using antiviral prophylaxis in subjects being treated with VELCADE. In the randomized studies in previously untreated and relapsed multiple myeloma, herpes zoster reactivation was more common in subjects treated with VELCADE (ranging between 6-11%) than in the control groups (3-4%). Herpes simplex was seen in 1-3% in subjects treated with VELCADE and 1-3% in the control groups. In the previously untreated multiple myeloma study, herpes zoster virus reactivation in the VELCADE, melphalan and prednisone arm was less common in subjects receiving prophylactic antiviral therapy (3%) than in subjects who did not receive prophylactic antiviral therapy (17%).

Retreatment In Relapsed Multiple Myeloma

A single-arm trial was conducted in 130 patients with relapsed multiple myeloma to determine the efficacy and safety of retreatment with intravenous VELCADE. The safety profile of patients in this trial is consistent with the known safety profile of VELCADE-treated patients with relapsed multiple myeloma as demonstrated in Tables 10, 11, and 13; no cumulative toxicities were observed upon retreatment. The most common adverse drug reaction was thrombocytopenia which occurred in 52% of the patients. The incidence of ≥ Grade 3 thrombocytopenia was 24%. Peripheral neuropathy occurred in 28% of patients, with the incidence of ≥ Grade 3 peripheral neuropathy reported at 6%. The incidence of serious adverse reactions was 12.3%. The most commonly reported serious adverse reactions were thrombocytopenia (3.8%), diarrhea (2.3%), and herpes zoster and pneumonia (1.5% each).

Adverse reactions leading to discontinuation occurred in 13% of patients. The reasons for discontinuation included peripheral neuropathy (5%) and diarrhea (3%).

Two deaths considered to be VELCADE-related occurred within 30 days of the last VELCADE dose; one in a patient with cerebrovascular accident and one in a patient with sepsis.

Additional Adverse Reactions From Clinical Studies

The following clinically important serious adverse reactions that are not described above have been reported in clinical trials in patients treated with VELCADE administered as monotherapy or in combination with other chemotherapeutics. These studies were conducted in patients with hematological malignancies and in solid tumors.

Blood and lymphatic system disorders: Anemia, disseminated intravascular coagulation, febrile neutropenia, lymphopenia, leukopenia

Cardiac disorders: Angina pectoris, atrial fibrillation aggravated, atrial flutter, bradycardia, sinus arrest, cardiac amyloidosis, complete atrioventricular block, myocardial ischemia, myocardial infarction, pericarditis, pericardial effusion, Torsades de pointes, ventricular tachycardia

Ear and labyrinth disorders: Hearing impaired, vertigo

Eye disorders: Diplopia and blurred vision, conjunctival infection, irritation

Gastrointestinal disorders: Abdominal pain, ascites, dysphagia, fecal impaction, gastroenteritis, gastritis hemorrhagic, hematemesis, hemorrhagic duodenitis, ileus paralytic, large intestinal obstruction, paralytic intestinal obstruction, peritonitis, small intestinal obstruction, large intestinal perforation, stomatitis, melena, pancreatitis acute, oral mucosal petechiae, gastroesophageal reflux

General disorders and administration site conditions: Chills, edema, edema peripheral, injection site erythema, neuralgia, injection site pain, irritation, malaise, phlebitis

Hepatobiliary disorders: Cholestasis, hepatic hemorrhage, hyperbilirubinemia, portal vein thrombosis, hepatitis, liver failure

Immune system disorders: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, laryngeal edema

Infections and infestations: Aspergillosis, bacteremia, bronchitis, urinary tract infection, herpes viral infection, listeriosis, nasopharyngitis, pneumonia, respiratory tract infection, septic shock, toxoplasmosis, oral candidiasis, sinusitis, catheter related infection

Injury, poisoning and procedural complications: Catheter related complication, skeletal fracture, subdural hematoma

Investigations: Weight decreased

Metabolism and nutrition disorders: Dehydration, hypocalcemia, hyperuricemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia

Musculoskeletal and connective tissue disorders: Arthralgia, back pain, bone pain, myalgia, pain in extremity

Nervous system disorders: Ataxia, coma, dizziness, dysarthria, dysesthesia, dysautonomia, encephalopathy, cranial palsy, grand mal convulsion, headache, hemorrhagic stroke, motor dysfunction, neuralgia, spinal cord compression, paralysis, postherpetic neuralgia, transient ischemic attack

Psychiatric disorders: Agitation, anxiety, confusion, insomnia, mental status change, psychotic disorder, suicidal ideation

Renal and urinary disorders: Calculus renal, bilateral hydronephrosis, bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, renal failure (acute and chronic), glomerular nephritis proliferative

Respiratory, thoracic and mediastinal disorders: Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, chronic obstructive airways disease exacerbated, cough, dysphagia, dyspnea, dyspnea exertional, epistaxis, hemoptysis, hypoxia, lung infiltration, pleural effusion, pneumonitis, respiratory distress, pulmonary hypertension

Skin and subcutaneous tissue disorders: Urticaria, face edema, rash (which may be pruritic), leukocytoclastic vasculitis, pruritus.

Vascular disorders: Cerebrovascular accident, cerebral hemorrhage, deep venous thrombosis, hypertension, peripheral embolism, pulmonary embolism, pulmonary hypertension

Postmarketing Experience

The following adverse reactions have been identified from the worldwide postmarketing experience with VELCADE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Cardiac disorders: Cardiac tamponade

Ear and labyrinth disorders: Deafness bilateral

Eye disorders: Optic neuropathy, blindness

Gastrointestinal disorders: Ischemic colitis

Infections and infestations: Progressive multifocal leukoencephalopathy (PML), ophthalmic herpes, herpes meningoencephalitis

Nervous system disorders: Posterior reversible encephalopathy syndrome (PRES, formerly RPLS)

Respiratory, thoracic and mediastinal disorders: Acute diffuse infiltrative pulmonary disease

Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute febrile neutrophilic dermatosis (Sweet’s syndrome)

Read the entire FDA prescribing information for Velcade (Bortezomib)

Read More »

Usual Adult Dose for Multiple Myeloma

FOR USE IN THE TREATMENT OF PREVIOUSLY UNTREATED MULTIPLE MYELOMA:
-Usual dose: 1.3 mg/m2 administered as a 3 to 5 second bolus IV injection or subcutaneously in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles:
-In cycles 1 through 4, bortezomib is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29, and 32). In cycles 5 through 9, bortezomib is administered once weekly (days 1, 8, 22, and 29).

Comments:
-At least 72 hours should elapse between consecutive doses of bortezomib.

FOR USE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA:
-Usual dose: 1.3 mg/m2 as a bolus intravenous injection or subcutaneously twice weekly for two weeks (days 1, 4, 8, and 11) followed by a ten day rest period (days 12 through 21). Therapy extending beyond 8 cycles may be administered by the standard schedule or may be given once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest (days 23 through 35).

Comments:
-Bortezomib may be administered alone or in combination with dexamethasone.
-The three week period is considered a treatment cycle.
-A minimum of 72 hours should elapse between consecutive doses of bortezomib.
-Patients with multiple myeloma who have previously responded to treatment with bortezomib (either alone or in combination) and who have relapsed at least 6 months after their prior therapy may be started on the last tolerated dose.

Use: For the treatment of multiple myeloma (who had previously responded to treatment with this drug and who have relapsed at least 6 months after completing treatment)

Precautions

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Consult WARNINGS section for additional precautions.

Dialysis

Because dialysis may reduce bortezomib concentrations, the drug should be administered after the dialysis procedure.

(web3)